Recent Oral Contraceptive Use by Formulation and Breast Cancer Risk among Women 20 to 49 Years of Age

被引:67
|
作者
Beaber, Elisabeth F. [1 ,2 ,3 ]
Buist, Diana S. M. [1 ,3 ]
Barlow, William E. [4 ]
Malone, Kathleen E. [2 ,3 ]
Reed, Susan D. [1 ,2 ,3 ,5 ]
Li, Christopher I. [2 ,3 ]
机构
[1] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA
[2] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA
[3] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
[4] Univ Washington, Dept Biostat, Seattle, WA 98195 USA
[5] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA
关键词
YOUNG-WOMEN; UNITED-STATES; EPITHELIAL PROLIFERATION; HORMONAL CONTRACEPTIVES; ESTROGEN-RECEPTOR; HISTORIES; PROGESTINS; COHORT; TRENDS;
D O I
10.1158/0008-5472.CAN-13-3400
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Previous studies of oral contraceptives and breast cancer indicate that recent use slightly increases risk, but most studies relied on self-reported use and did not examine contemporary oral contraceptive formulations. This nested case-control study was among female enrollees in a large U. S. integrated health care delivery system. Cases were 1,102 women ages 20 to 49 years diagnosed with invasive breast cancer from 1990 to 2009. Controls were randomly sampled from enrollment records (n = 21,952) and matched to cases on age, year, enrollment length, and medical chart availability. Detailed oral contraceptive use information was ascertained from electronic pharmacy records and analyzed using conditional logistic regression, ORs, and 95% confidence intervals (CI). Recent oral contraceptive use (within the prior year) was associated with an increased breast cancer risk (OR, 1.5; 95% CI, 1.3-1.9) relative to never or former OC use. The association was stronger for estrogen receptor-positive (ER+; OR, 1.7; 95% CI, 1.3-2.1) than estrogen receptor-negative (ER-) disease (OR, 1.2, 95% CI, 0.8-1.8), although not statistically significantly different (P = 0.15). Recent use of oral contraceptives involving high-dose estrogen (OR, 2.7; 95% CI, 1.1-6.2), ethynodiol diacetate (OR, 2.6; 95% CI, 1.4-4.7), or triphasic dosing with an average of 0.75 mg of norethindrone (OR, 3.1; 95% CI, 1.9-5.1; P-heterogeneity compared with using other oral contraceptives = 0.004) was associated with particularly elevated risks, whereas other types, including low-dose estrogen oral contraceptives, were not (OR, 1.0; 95% CI, 0.6-1.7). Our results suggest that recent use of contemporary oral contraceptives is associated with an increased breast cancer risk, which may vary by formulation. If confirmed, consideration of the breast cancer risk associated with different oral contraceptive types could impact discussions weighing recognized health benefits and potential risks. (C)2014 AACR.
引用
收藏
页码:4078 / 4089
页数:12
相关论文
共 50 条
  • [31] Oral contraceptive use and breast cancer risk: Current status
    Cerhan, James R.
    MAYO CLINIC PROCEEDINGS, 2006, 81 (10) : 1287 - 1289
  • [32] Oral contraceptive (OC) use and risk of breast cancer - reply
    L Tryggvadóttir
    H Tulinius
    GB Gudmundsdóttir
    British Journal of Cancer, 1997, 76 : 417 - 418
  • [33] Oral contraceptive (OC) use and risk of breast cancer - Reply
    Tryggvadottir, L
    Tulinius, H
    Gudmundsdottir, GB
    BRITISH JOURNAL OF CANCER, 1997, 76 (03) : 417 - 418
  • [34] Breast Cancer Risk Related to Combined Oral Contraceptive Use
    Graafland, Laura
    Abbott, Maura
    Accordino, Melissa
    JNP-JOURNAL FOR NURSE PRACTITIONERS, 2020, 16 (02): : 116 - 120
  • [35] Modification of oral contraceptive relationships on breast cancer risk by selected factors among younger women
    Brinton, LA
    Gammon, MD
    Malone, KE
    Schoenberg, JB
    Daling, JR
    Coates, RJ
    CONTRACEPTION, 1997, 55 (04) : 197 - 203
  • [36] Oral contraceptive use and risk of breast cancer by histologic type
    Newcomer, LM
    Newcomb, PA
    Trentham-Dietz, A
    Longnecker, MP
    Greenberg, R
    INTERNATIONAL JOURNAL OF CANCER, 2003, 106 (06) : 961 - 964
  • [38] Effect of Depo-Medroxyprogesterone Acetate on Breast Cancer Risk among Women 20 to 44 Years of Age
    Li, Christopher I.
    Beaber, Elisabeth F.
    Tang, Mei Tzu Chen
    Porter, Peggy L.
    Daling, Janet R.
    Malone, Kathleen E.
    CANCER RESEARCH, 2012, 72 (08) : 2028 - 2035
  • [39] A PROSPECTIVE-STUDY OF ORAL-CONTRACEPTIVE USE AND THE RISK OF BREAST-CANCER IN WOMEN
    ROMIEU, I
    WILLETT, WC
    COLDITZ, GA
    STAMPFER, MJ
    ROSNER, B
    HENNEKENS, C
    SPEIZER, FE
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 1989, 130 (04) : 812 - 812
  • [40] PROSPECTIVE-STUDY OF ORAL-CONTRACEPTIVE USE AND RISK OF BREAST-CANCER IN WOMEN
    ROMIEU, I
    WILLETT, WC
    COLDITZ, GA
    STAMPFER, MJ
    ROSNER, B
    HENNEKENS, CH
    SPEIZER, FE
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (17): : 1313 - 1321